Pilot study of abbreviated chemotherapy based on early positron emission tomography in Hodgkin lymphoma
Update: this study is closed to enrollment.
Patients in this study will be treated with ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) on Days 1 and 15 of each cycle according to standard treatment guidelines. The purpose of this study is to determine the progression-free survival at 36 months for patients with Hodgkin lymphoma who achieve a response after one cycle of ABVD chemotherapy.
Click here for more information on this study for people with untreated Hodgkin lymphoma or call June Greenberg, RN at (212) 746-2651.